Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540866 | 0.90 | HTT (0.50) | TSHRHTTHCRTR1HPGDNPC1 | |
| SCHEMBL9012225 | 0.88 | ALOX5 (0.49) | TSHRHTTHCRTR1HPGDSMN1; SMN2 | |
| SCHEMBL16157270 | 0.86 | KMT2A (0.41) | TSHRHTTHPGDSMN1; SMN2KDM4E | |
| SCHEMBL6609811 | 0.85 | ALDH1A1 (0.51) | TSHRHTTHCRTR1RAB9AHPGD | |
| SCHEMBL24696326 | 0.83 | TSHR (0.57) | TSHRHTTHCRTR1HPGDKDM4E | |
| SCHEMBL14186001 | 0.83 | HPGD (0.47) | TSHRHTTHCRTR1RAB9AHPGD | |
| SCHEMBL11953188 | 0.83 | TSHR (0.45) | TSHRHTTHCRTR1RAB9AHPGD | |
| SCHEMBL18074482 | 0.83 | HTT (0.53) | TSHRHTTHCRTR1HPGDNPC1 | |
| SCHEMBL14185996 | 0.83 | MAOB (0.47) | TSHRHTTHCRTR1RAB9AHPGD | |
| SCHEMBL27521277 | 0.83 | HTT (0.45) | TSHRHTTHCRTR1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970303-B3 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20120322886-A1 | USE OF A SATURATED AMINES COMPOUND IN MANUFACTURE OF MEDICAMENTS FOR MOBILIZING PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL | Institute of Transfusion Medicine, Academy of Mili -tary Medical Sciences, Peoples Liberation Army.. (CN) | 2012-12-20 | — | — | US | disclosed |
| EP-2510926-A1 | USE OF SATURATED AMINES COMPOUNDS IN MANUFACTURE OF MEDICAMENTS FOR MOBILIZING PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2012-10-17 | — | — | EP | disclosed |
| EP-2223971-A1 | Long wavelength thiol-reactive fluorophores | Becton, Dickinson & Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1282420-A4 | HALOGENATED 2-AMINO-3, 4 HEPTENOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORP (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6586471-B1 | Oxidoreductase inhibitors such as 2-amino-4-fluoro-7-((1-iminoethyl)amino)-3-heptenoic acid, dihydrochloride used as preferential antiinflammatory and antiproliferative agents | G. D. SEARLE | 2003-07-01 | — | — | US | disclosed |
| EP-1282420-A2 | HALOGENATED 2-AMINO-3, 4 HEPTENOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001078654-A2 | HALOGENTATED 2-AMINO-3, 4 HEPTENOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322886-A1 | USE OF A SATURATED AMINES COMPOUND IN MANUFACTURE OF MEDICAMENTS FOR MOBILIZING PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL | CCL11, MYADM, CD14 | TSHR 4235/4885HTT 441/4885PTGS2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.